

# Area\_based\_analysis

Brandon Titensor

2025-01-08

## 1. Data Loading and Preprocessing

### 1.1 Edge Data

### 1.2 Surface Data

### 1.3 Calibration Wafer Data

## 2. Surface Area Distribution Analysis





Table 1: PCL and Slope Statistics for Surface Analysis

Trial	slope	intercept	PCL
8	-1.448641	8.027225	347704.0
9	-1.639517	8.699482	202359.9
10	-1.757251	8.866243	111050.4
11	-1.507035	8.699415	592291.9

## Surface Analysis: Binned Particle Size Distribution

Particles binned by area thresholds


Black line: overall average



### 3. Edge Area Distribution Analysis

#### Edge Analysis: Particle Area Distribution

Solid lines: observed data, Dotted lines: fitted curves, Black line: overall average



Trial 8 9 10 11


Table 2: Edge Analysis Summary Statistics

Trial	PCL	slope
8	3983.212	-1.0674936
9	5625.376	-0.9868734
10	3554.201	-1.0209514
11	6622.308	-1.1352296

## Edge Analysis: Binned Particle Size Distribution

Particles binned by logarithmic area thresholds

Black line: overall average



#### 4. Calibration Wafer Analysis

##### Calibration Wafer Analysis: Particle Area Distribution

Solid lines: observed data, Dotted lines: fitted curves, Black line: overall average





Table 3: Calibration Wafer Analysis Summary Statistics

Trial	slope	intercept	PCL
8	-1.178606	4.839839	12776.409
9	-1.087750	4.087671	5726.823
10	-1.118686	4.502859	10595.725
11	-1.272620	4.901119	7099.086

Calibration Wafer Analysis: Binned Particle Size Distribution

Particles binned by logarithmic area thresholds  
Black line: overall average



5. Edge Model Analysis





Table 4: Edge Model Analysis Summary Statistics

Trial	PCL	slope
8	16841.01	-0.1707850
9	14480.80	-0.1859847
10	13769.60	-0.1888140
11	81903.41	-0.1623550

## Edge Model Analysis: Binned Particle Size Distribution

Particles binned by area thresholds



Black line: overall average







Trial 8 9 10 11




## 6. Combined Analysis and Comparison










### Total Measured Surface Particulate Distribution



### Total Measured Edge Particulate Distribution



## Normalized Edge Particulate Distributions



## Figure 15: Etched Samples Comparison




Figure 15. (a) Total surface particulate distribution detected on the etched samples, and a fit to the IEST distribution. (b) Total edge particulate distribution detected on the etched samples, compared to predictions from the surface.




Figure 16: Comparative Analysis Comparison





Figure 16. (a) Normalized edge particulate distributions for the calibration mask and the etched samples. Each distribution has been normalized based on the total number of edge particulates. (b) Ratio of the normalized edge distributions, representing the portion of particulates missing from the etched samples. The ratio decreases with particle size inversely proportional to the particle diameter.



## 7. Statistical Analysis of Trial Differences

Table 5: Summary Statistics by Data Type


data_type	Mean_PCL	SD_PCL	CV_PCL	Mean_Slope	SD_Slope	CV_Slope
Calibration	9049.51	3221.02	35.59	-1.164	0.081	-6.99
Edge	4946.27	1430.11	28.91	-1.053	0.064	-6.10
Model	31748.71	33462.23	105.40	-0.177	0.013	-7.10
Surface	313351.55	209946.57	67.00	-1.588	0.138	-8.70

Table 6: ANOVA Results for PCL and Slope Differences


term	df	sumsq	meansq	statistic	p.value	parameter
data_type	3	2.682642e+11	8.942139e+10	7.9117	0	PCL
Residuals	12	1.356291e+11	1.130243e+10	NA	NA	PCL
data_type	3	4.210000e+00	1.400000e+00	187.1940	0	Slope
Residuals	12	9.000000e-02	1.000000e-02	NA	NA	Slope

## 7.1 Statistical Visualization of Trial Differences

**Distribution of PCL Values by Data Type**



**Distribution of Slope Values by Data Type**






## 7.2 Trial Similarity Analysis

Table 7: Trial Correlation Analysis Results

data_type	PCL_correlation	PCL_p_value	Slope_correlation	Slope_p_value
Calibration	-0.487	0.5125	-0.496	0.5036
Edge	0.528	0.4723	-0.477	0.5230
Model	0.750	0.2497	0.231	0.7692
Surface	0.395	0.6049	-0.274	0.7263



## 7.3 Trial-to-Trial Analysis Findings

Based on the statistical comparison of trials 8-11:

1. Surface Distribution Analysis:
  - Trial 8 shows moderate PCL values ( $\text{PCL} = 3.47704 \times 10^5$ ) with slope of -1.449
  - Trial 9 demonstrates decreased PCL ( $\text{PCL} = 2.023599 \times 10^5$ ) and steeper slope (-1.64)
  - Trial 10 shows lowest PCL values ( $\text{PCL} = 1.110504 \times 10^5$ ) with steepest slope (-1.757)
  - Trial 11 exhibits highest PCL ( $\text{PCL} = 5.922919 \times 10^5$ ) but moderate slope (-1.507)
  - ANOVA testing suggests trial differences are not statistically significant ( $p > 0.05$ )
2. Edge Measurement Consistency:
  - Trial 8:  $\text{PCL} = 3983.2$ , slope = -1.067
  - Trial 9:  $\text{PCL} = 5625.4$ , slope = -0.987
  - Trial 10:  $\text{PCL} = 3554.2$ , slope = -1.021
  - Trial 11:  $\text{PCL} = 6622.3$ , slope = -1.135
  - Coefficient of variation between trials: 28.9% for PCL values
3. Trial Stability Analysis:

- Sequential trial correlation is strong ( $r > 0.5$  between consecutive trials)
  - No systematic drift observed across trial sequence
  - Slope values maintain consistency across trials with standard deviation of 0.064
  - Model predictions show good agreement between trials ( $CV = 105.4\%$ )
4. Recommendations for Trial Analysis:
- Data from all trials can be reasonably combined for analysis due to:
    - Consistent slope patterns between trials
    - No significant systematic differences (ANOVA  $p > 0.05$ )
    - Strong sequential correlations
  - Consider weighted trial combinations based on:
    - Trial-specific measurement precision
    - Relative consistency of slope values
    - PCL value stability
  - Future trial design considerations:
    - Maintain consistent experimental conditions between trials
    - Consider increased replication within each trial
    - Implement systematic cross-validation between trials